OS Therapies Stock Jumps on Bullish Analyst Initiation and Upcoming Drug Filings

Shares of OS Therapies (OSTX) surged approximately 11.0% in morning trading after Roth/MKM initiated coverage on the clinical-stage oncology company with a Buy rating and a $7.00 price target.

Analyst Confidence Grows

The new coverage from Roth/MKM expands the analyst consensus on OS Therapies to four Buy ratings with no holds or sells, according to Investing.com. The firm's positive outlook centers on the company's lead asset, OST-HER2, a gene-edited immunotherapy for treating osteosarcoma.

The initiation follows a reiterated Buy rating from Lake Street on July 7, signaling sustained bullish sentiment from the analyst community. This institutional endorsement provides a significant boost for the small-cap biotechnology firm as it approaches several critical milestones.

Key Regulatory Catalysts Ahead

Investor focus is fixed on a series of upcoming regulatory submissions for OST-HER2 across multiple international markets. In a Q3 2026 corporate outlook published on July 6, OS Therapies outlined a clear roadmap for investors, including:

Ad

• A submission to the European Medicines Agency (EMA) for conditional marketing authorization by September 30, 2026.
• A Biologics License Application (BLA) submission to the U.S. Food and Drug Administration (FDA) under the Accelerated Approval Program by the end of 2026.

These near-term events in the U.S., Europe, the U.K., and Australia represent major potential catalysts for the company.

Financial and Market Context

The stock's rally was also supported by a recent financing deal and a constructive broader market. The company recently secured up to $10 million in a convertible note financing, with an initial tranche funded on July 2, extending its operational runway into 2027 and reducing near-term balance sheet concerns.

Shares reached a session high of $1.62, moving well above the 52-week low of $1.15, though still below the 52-week high of $2.57. The move came as the S&P 500 and Nasdaq posted modest gains, providing a favorable backdrop for risk assets like biotechnology stocks.